English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT04285567 /

CO41685

A Prospective, Open-Label, Multicenter Randomized Phase III Study To Compare The Efficacy And Safety Of A Combined Regimen Of Venetoclax And Obinutuzumab Versus Fludarabine, Cyclophosphamide, And Rituximab (FCR)/Bendamustine And Rituximab (BR) In FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL(17P) Or TP53 Mutation

DISEASE GROUP:
Lymphoma
current phase:
Phase III
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: